Yes, Japan conducts post-audit follow-up inspections for drug quality issues. These inspections ensure compliance with Good Manufacturing Practices (GMP) and address any deficiencies identified during initial audits. The Pharmaceuticals and Medical Devices Agency (PMDA) oversees these processes to maintain high standards of drug safety and efficacy in the market.
